The role of FSCN1 in migration and invasion of pituitary adenomas

Liu, Chunhui; Gao, Hua; Cao, Lei; Gui, Songbai; Liu, Qian; Li, Chuzhong; Li, Dan; Gong, Lei; Zhang, Yazhou

doi:10.1016/j.mce.2015.10.021

Cited by 36 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Slides were dried at room temperature for 24–48 h and stored in a freezer at −80 °C until use. To minimize loss of antigenicity, sections were processed within 1 week of cutting [20]. …”

Section: Methodsmentioning

confidence: 99%

Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas

Yao

Gao

et al. 2017

J Neurooncol

Self Cite

View full text Add to dashboard Cite

Nonfunctioning pituitary adenomas (NFPAs) are the most prevalent type of pituitary macro-adenoma. Clarifying the relationship between NFPA markers and disease progression or recurrence could provide a basis for administration of adjuvant treatments. The present study examined the expression levels of high-mobility group (HMG)A1, Ki-67, mouse double minute 2 homolog (MDM2), and retinoblastoma (RB)with respect to NFPA recurrence. Immunohistochemistry was carried out using antibodies to Ki-67, MDM2, HMGA-1, and RB on tissue microarray slides of a cohort of 35 paired NFPA samples of primary and recurrence/regrowth tumors. Based on postoperative magnetic resonance imaging data, tumors were classified as recurrence (n = 20) included primary and recurrent tumors or regrowth (n = 15) included primary and regrowth tumors, which are paired. Protein expression was classified as negative or positive according to the H-score method and was analyzed with respect to clinical and pathological findings. MDM2-positive cases accounted for11/20 primary and 19/20 s recurrent tumors (χ2 = 8.533, P = 0.003), and 9/15 primary tumors and 15/15 s regrowth tumors (χ2 = 7.5, P = 0.006). MGA1-positive cases represented 9/20 primary tumors and 16/20 s recurrent tumors (χ2 = 5.227, P = 0.022), and 4/15 primary tumors and 12/15 s regrowth tumors (χ2 = 8.571, P = 0.003). There was no statistically significant difference in Ki-67 expression between primary and second recurrent/regrowth tumors although theKi67 labeling index was higher in the latter groups. RB was highly expressed in all groups with no significant difference between them. HMGA1 and MDM2 were more highly expressed in recurrence/regrowth cases of NFPA than in primary NFPA. HMGA1 and MDM2 are biomarkers and potential drug targets for NFPA treatment.

show abstract

Section: Methodsmentioning

confidence: 99%

Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas

Yao

Gao

et al. 2017

J Neurooncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…The slides were scanned with Aperio Scanscope software using Aperio AT2. Staining value of slides (0-300) was evaluated as describes previously [19].…”

Section: Immunohistochemistry (Ihc) Stainingmentioning

confidence: 99%

miRNA-199a-5p functions as a tumor suppressor in prolactinomas

et al. 2019

View full text Add to dashboard Cite

Prolactinomas are the most frequently observed pituitary adenomas (PAs), and 5%–18% tumors were resistant to the dopamine agonists (DAs). MicroRNAs (miRNAs) dysfunction play a key role in tumorigenesis. Agilent miRNA and an expression chip were used for six prolactinomas and three normal pituitary specimens. Differentially expressed genes were confirmed by RT-qPCR. The level of DDR1 and SAT1 was determined with tissue micro-array (TMA) and western blot. A MMQ cell line was used for functional experiments. We have identified 5-miRNA and 12 target gene signatures of prolactinomas through gene ontology analysis. miRNA-199a-5p was selected for experiments that integrated the results from prolactinomas specimens and a rat prolactinoma model induced by 17-b-estradiol. Tumors with low miRNA-199a-5p had a significantly invasive behavior and a higher tumor volume (p<0.05). DDR1 and SAT1, target genes of miRNA-199a-5p, had higher H-scores in the invasive group than those of the non-invasive group through TMA. An overexpression of miRNA-119a-5p suppressed the PRL secretion and the cell viability through upregulated the apoptosis level in MMQ cells (p<0.01). Furthermore, we found the target genes expression of DDR1 and SAT1 were affected by miRNA-199a-5p regardless of mRNA levels or protein levels. This study provided evidence that downregulation of miRNA-199a-5p may contribute to prolactinoma tumorigenesis.

show abstract

“…Regarding actin-binding proteins, a role in regulating migration and invasion of pituitary adenomas has been attributed to fascin, which organizes actin filaments in parallel bundles (Liu et al 2016). The authors demonstrated that silencing of fascin in GH3 cells reduced cell invasion, with a mechanism involving NOTCH1/DLL pathway.…”

Section: Introductionmentioning

confidence: 99%

Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors

Mantovani

Treppiedi

Giardino

et al. 2019

Endocrine-Related Cancer

View full text Add to dashboard Cite

Although generally benign, pituitary tumors are frequently locally invasive, with reduced success of neurosurgery and unresponsive to pharmacological treatment with somatostatin or dopamine analogues. The molecular basis of the different biological behavior of pituitary tumors are still poorly identified, but a body of work now suggests that the activity of specific cytoskeleton proteins is a key factor regulating both the invasiveness and drug resistance of these tumors. This review recapitulates the experimental evidence supporting a role for the actin-binding protein filamin A (FLNA) in the regulation of somatostatin and dopamine receptors expression and signaling in pituitary tumors, thus in determining the responsiveness to currently used drugs, somatostatin analogues and dopamine receptor type 2 agonists. Regarding the regulation of invasive behavior of pituitary tumoral cells, we bring evidence to the role of the actin-severing protein cofilin, whose activation status may be modulated by dopaminergic and somatostatinergic drugs, through FLNA involvement. Molecular mechanisms involved in the regulation of FLNA expression and function in pituitary tumors will also be discussed.

show abstract

The role of FSCN1 in migration and invasion of pituitary adenomas

Cited by 36 publications

References 41 publications

Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas

Analysis of Ki67, HMGA1, MDM2, and RB expression in nonfunctioning pituitary adenomas

miRNA-199a-5p functions as a tumor suppressor in prolactinomas

Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors

Contact Info

Product

Resources

About